Genetic modulation of oral anticoagulation with warfarin

M. Margaglione, D. Colaizzo, G. D'Andrea, V. Brancaccio, A. Ciampa, E. Grandone, G. Di Minno

Research output: Contribution to journalArticle

Abstract

Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurrence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications. The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffe's test) or the CYP2C9*3 haplotype (4.0 mg; p

Original languageEnglish
Pages (from-to)775-778
Number of pages4
JournalThrombosis and Haemostasis
Volume84
Issue number5
Publication statusPublished - 2000

Fingerprint

Warfarin
Hemorrhage
Haplotypes
Genes
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Cytochrome P-450 CYP2C9
Incidence

Keywords

  • 450 CYP2C9
  • Bleeding
  • Dose requirement
  • Polymorphisms
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

Margaglione, M., Colaizzo, D., D'Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., & Di Minno, G. (2000). Genetic modulation of oral anticoagulation with warfarin. Thrombosis and Haemostasis, 84(5), 775-778.

Genetic modulation of oral anticoagulation with warfarin. / Margaglione, M.; Colaizzo, D.; D'Andrea, G.; Brancaccio, V.; Ciampa, A.; Grandone, E.; Di Minno, G.

In: Thrombosis and Haemostasis, Vol. 84, No. 5, 2000, p. 775-778.

Research output: Contribution to journalArticle

Margaglione, M, Colaizzo, D, D'Andrea, G, Brancaccio, V, Ciampa, A, Grandone, E & Di Minno, G 2000, 'Genetic modulation of oral anticoagulation with warfarin', Thrombosis and Haemostasis, vol. 84, no. 5, pp. 775-778.
Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E et al. Genetic modulation of oral anticoagulation with warfarin. Thrombosis and Haemostasis. 2000;84(5):775-778.
Margaglione, M. ; Colaizzo, D. ; D'Andrea, G. ; Brancaccio, V. ; Ciampa, A. ; Grandone, E. ; Di Minno, G. / Genetic modulation of oral anticoagulation with warfarin. In: Thrombosis and Haemostasis. 2000 ; Vol. 84, No. 5. pp. 775-778.
@article{67c7cbe7e7d4456fb403a11c970cd3e3,
title = "Genetic modulation of oral anticoagulation with warfarin",
abstract = "Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurrence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications. The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffe's test) or the CYP2C9*3 haplotype (4.0 mg; p",
keywords = "450 CYP2C9, Bleeding, Dose requirement, Polymorphisms, Warfarin",
author = "M. Margaglione and D. Colaizzo and G. D'Andrea and V. Brancaccio and A. Ciampa and E. Grandone and {Di Minno}, G.",
year = "2000",
language = "English",
volume = "84",
pages = "775--778",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Genetic modulation of oral anticoagulation with warfarin

AU - Margaglione, M.

AU - Colaizzo, D.

AU - D'Andrea, G.

AU - Brancaccio, V.

AU - Ciampa, A.

AU - Grandone, E.

AU - Di Minno, G.

PY - 2000

Y1 - 2000

N2 - Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurrence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications. The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffe's test) or the CYP2C9*3 haplotype (4.0 mg; p

AB - Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurrence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications. The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffe's test) or the CYP2C9*3 haplotype (4.0 mg; p

KW - 450 CYP2C9

KW - Bleeding

KW - Dose requirement

KW - Polymorphisms

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=0033694203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033694203&partnerID=8YFLogxK

M3 - Article

C2 - 11127854

AN - SCOPUS:0033694203

VL - 84

SP - 775

EP - 778

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -